


Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended): A compound of formula (I)



wherein:

Z_1 is N;

R^1 and R^{1a} are independently is hydrogen; hydroxy; (C_{1-6})alkoxy unsubstituted or substituted by (C_{1-6})alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two (C_{1-6})alkyl, acyl, (C_{1-6})alkylsulphonyl, $CONH_2$, hydroxy, (C_{1-6})alkylthio, heterocyclithio, heterocyclxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6})alkylsulphonyloxy; (C_{1-6})alkoxy-substituted (C_{1-6})alkyl; halogen; (C_{1-6})alkyl; (C_{1-6})alkylthio; trifluoromethyl; trifluoromethoxy; nitro; azido; cyano; acyl; acyloxy; acylthio; (C_{1-6})alkylsulphonyl; (C_{1-6})alkylsulphoxide; arylsulphonyl; arylsulphoxide; or an amino, piperidyl, guanidino or amidino group unsubstituted or N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups; or R^4 and R^{1a} may together form ethylenedioxy;

R^2 is H or halogen;

provided that when Z_1 is N, then R^2 is H;

R^3 is hydrogen; halogen; hydroxy; cyano; CF_3 ; nitro; azido; acyl; aryl; heteroaryl; CO_2H ; acetoxyacyloxy; acylthio; (C_{1-6})alkyl unsubstituted or substituted by one or two (C_{1-6})alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two (C_{1-6})alkyl, acyl, (C_{1-6})alkylsulphonyl, $CONH_2$, hydroxy, (C_{1-6})alkylthio, heterocyclithio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6})alkylsulphonyloxy; (C_{1-6})alkoxy unsubstituted or substituted by one or two (C_{1-6})alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two (C_{1-6})alkyl, acyl, (C_{1-6})alkylsulphonyl, $CONH_2$, hydroxy, (C_{1-6})alkylthio, heterocyclithio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6})alkylsulphonyloxy; (C_{3-7})cycloalkyl; (C_{1-6})alkoxy-substituted(C_{1-6})alkyl; (C_{1-6})alkylthio; trifluoromethoxy; (C_{1-6})alkylsulphonyl; (C_{1-6})alkylsulphoxide; arylsulphonyl; or arylsulphoxide; or an amino, piperidyl, guanidino or amidino group unsubstituted or N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups;

w_1 is N, C, or CR^4 ;

w_2 is $C=O$, CR^4 , or CR^4R^5 ;

w_3 is $C=O$ or CR^4R^5 ;

w_4 is N or CR^4 ;

w_5 is $C=O$ or CR^4R^5 ;

w_6 is $C=O$, CR^4 , or CR^4R^5 ;

or, one of w_2 , w_3 , w_5 and w_6 is $CR^4R^5CR^4R^5$ and the others are defined as above;
wherein each R^4 and R^5 is independently hydrogen; halogen;
hydroxy; cyano; CF_3 ; nitro; azido; acyl; aryl; heteroaryl; CO_2H ;
acetoxyacyloxy; acylthio; (C_{1-6})alkyl unsubstituted or substituted by one or two (C_{1-6})alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two (C_{1-6})alkyl, acyl, (C_{1-6})alkylsulphonyl, $CONH_2$, hydroxy, (C_{1-6})alkylthio, heterocyclithio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6})alkylsulphonyloxy;

6)alkylsulphonyloxy; (C₁₋₆)alkoxy unsubstituted or substituted by one or two (C₁₋₆)alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two (C₁₋₆)alkyl, acyl, (C₁₋₆)alkylsulphonyl, CONH₂, hydroxy, (C₁₋₆)alkylthio, heterocyclylthio, heterocyclxyloxy, arylthio, aryloxy, acylthio, acyloxy or (C₁₋₆)alkylsulphonyloxy; (C₃₋₇)cycloalkyl; (C₁₋₆)alkoxy-substituted(C₁₋₆)alkyl; (C₁₋₆)alkylthio; trifluoromethoxy; (C₁₋₆)alkylsulphonyl; (C₁₋₆)alkylsulphoxide; arylsulphonyl; or arylsulphoxide; or an amino, piperidyl, guanidino or amidino group unsubstituted or N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups; or two R⁵ groups are joined together to form bicycloheptane;

A is CR⁶R⁷ or C(O);


B is CR⁸R⁹ or C(O);

wherein R⁶, R⁷, R⁸, and R⁹ are independently hydrogen; halogen; hydroxy; cyano; CF₃; nitro; azido; acyl; aryl; heteroaryl; CO₂H; acyloxy; acylthio; (C₁₋₆)alkyl unsubstituted or substituted by one or two (C₁₋₆)alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two (C₁₋₆)alkyl, acyl, (C₁₋₆)alkylsulphonyl, CONH₂, hydroxy, (C₁₋₆)alkylthio, heterocyclylthio, heterocyclxyloxy, arylthio, aryloxy, acylthio, acyloxy or (C₁₋₆)alkylsulphonyloxy; (C₁₋₆)alkoxy unsubstituted or substituted by one or two (C₁₋₆)alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two (C₁₋₆)alkyl, acyl, (C₁₋₆)alkylsulphonyl, CONH₂, hydroxy, (C₁₋₆)alkylthio, heterocyclylthio, heterocyclxyloxy, arylthio, aryloxy, acylthio, acyloxy or (C₁₋₆)alkylsulphonyloxy; (C₃₋₇)cycloalkyl; (C₁₋₆)alkoxy-substituted(C₁₋₆)alkyl; (C₁₋₆)alkylthio; trifluoromethoxy; (C₁₋₆)alkylsulphonyl; (C₁₋₆)alkylsulphoxide; arylsulphonyl; or arylsulphoxide; or an amino, piperidyl, guanidino or amidino

group unsubstituted or N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups;

R¹⁰ is hydrogen; aryl; heteroaryl; (C₁₋₆)alkyl unsubstituted or substituted by one or two (C₁₋₆)alkoxy, acyloxy, carboxy, hydroxy, amino, piperidyl, piperazinyl, morpholino, guanidino, or amidino, any of which is unsubstituted or N-substituted by one or two aryl, heteroaryl, halogen, cyano, CF₃, unsubstituted (C₁₋₆)alkyl, acyl, (C₁₋₆)alkylsulphonyl, arylsulphonyl, hydroxy, (C₁₋₆)alkylthio, heterocyclithio, heterocyclxy, arylthio, aryloxy, acylthio, acyloxy, or (C₁₋₆)alkylsulphonyloxy, provided that the substitution does not lead to an unstable compound; (C₁₋₆)alkoxy-substituted (C₁₋₆)alkyl; hydroxy-substituted (C₁₋₆)alkyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenylcarbonyl; (C₁₋₆)alkoxycarbonyl; CO₂H; or CF₃;

R¹¹ is a group -U-R¹² where R¹² is a substituted or unsubstituted bicyclic carbocyclic or heterocyclic ring system (A):



containing up to four heteroatoms in each ring in which

at least one of rings (a) and (b) is aromatic;

X¹ is C or N when part of an aromatic ring or CR¹⁴ when part of a non aromatic ring;

X² is N, NR¹³, O, S(O)_X, CO or CR¹⁴ when part of an aromatic or non-aromatic ring or may in addition be CR¹⁴R¹⁵ when part of a non aromatic ring;

X³ and X⁵ are independently N or C;

Y¹ is a 0 to 4 atom linker group each atom of which is independently selected from N, NR¹³, O, S(O)_X, CO and CR¹⁴ when part of an aromatic or non-aromatic ring or may additionally be CR¹⁴R¹⁵ when part of a non aromatic ring,

Y^2 is a 2 to 6 atom linker group, each atom of Y^2 being independently selected from N, NR¹³, O, S(O)_x, CO and CR¹⁴ when part of an aromatic or non-aromatic ring or may additionally be CR¹⁴R¹⁵ when part of a non aromatic ring;

each of R¹⁴ and R¹⁵ is independently selected from: H; (C₁₋₄)alkylthio; halo; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; hydroxy; hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; trifluoromethoxy; nitro; cyano; carboxy; amino or aminocarbonyl unsubstituted or substituted by (C₁₋₄)alkyl;

each R¹³ is independently H; trifluoromethyl; (C₁₋₄)alkyl unsubstituted or substituted by hydroxy, carboxy, (C₁₋₄)alkoxy, (C₁₋₆)alkylthio, halo or trifluoromethyl; (C₂₋₄)alkenyl; or aminocarbonyl wherein the amino group is optionally substituted (C₁₋₄)alkyl;

each x is independently 0, 1 or 2;

U is CO, SO₂, CH₂, or CR¹⁶R¹⁷;

R¹⁶ and R¹⁷ are independently selected from H; aryl; heteroaryl; (C₁₋₆)alkyl; (C₁₋₆)alkyl substituted by (C₁₋₆)alkoxy, hydroxy, amino, piperidyl, piperazinyl, morpholino, guanidino, or amidino, any of which is substituted or N-substituted by one or two H, aryl, heteroaryl, halogen, cyano, CF₃, (C₁₋₆)alkyl, acyl, (C₁₋₆)alkylsulphonyl, arylsulphonyl, hydroxy, (C₁₋₆)alkylthio, heterocyclthio, heterocyclxy, arylthio, aryloxy, acylthio, acyloxy, or (C₁₋₆)alkylsulphonyloxy, provided that the substitution does not lead to an unstable compound; (C₁₋₆)alkoxy-substituted(C₁₋₆)alkyl; hydroxy-substituted(C₁₋₆)alkyl; amino-substituted(C₁₋₆)alkyl, which is N-substituted by one or two (C₁₋₆)alkyl, acyl, (C₁₋₆)alkylsulphonyl, or arylsulphonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenylcarbonyl; (C₁₋₆)alkoxycarbonyl; CO₂H; or CF₃; or

a pharmaceutically acceptable salt thereof.

2. (Previously presented): A compound or salt according to claim 1, wherein R¹ is F, Cl, OCH₃, methyl, or SCH₃.

3. Canceled.
4. (Previously presented): A compound or salt according to claim 1, wherein R² is H or F.
5. (Previously presented): A compound or salt according to claim 1, wherein R³ is Cl or F.
6. (Previously presented): A compound or salt according to claim 1, wherein each R⁴ is independently H, methyl, OH, COOH, NH₂, OCH₃, or CH₂OH.
7. (Previously presented): A compound or salt according to claim 1, wherein R⁵ is H.
8. (Previously presented): A compound or salt according to claim 1, wherein the group —U— is —CH₂—.
9. (Previously presented): A compound or salt according to claim 1, wherein R¹² is:
benzo[1,2,5]thiadiazol-5-yl;
4H-benzo[1,4] thiazin-3-one-6-yl;
2,3-dihydro-benzo[1,4]dioxin-6-yl;
benzo[1,2,3]thiadiazol-5-yl;
3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl;
7-fluoro-3-oxo-3,4-dihydro-2H-benzo[1,4] oxazin-6-yl;
2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazin-7-yl;
2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl;
3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl;
[1,2,3]thiadiazolo[5,4-b]pyridin-6-yl;
3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl;
7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl;
7-fluoro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl; or
2-oxo-2,3-dihydro-1H-pyrido[3,4-b][1,4]thiazin-7-yl.

10. (Currently amended): A compound according to claim 1, wherein the compound is:

6-({2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethylamino} methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethylamino} methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
(2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-{2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethyl}amine;
6-({2-[1-(3-chloro-6-methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({2-[1-(3-chloro-6-methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
{2-[1-(3-chloro-6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethyl}-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amine;
6-({2-[4-(6-methoxynaphthyridin-4-yl)piperazin-1-yl]ethylamino} methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({2-[4-(6-methoxynaphthyridin-4-yl)piperazin-1-yl]ethylamino} methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
(2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-{2-[4-(6-methoxynaphthyridin-4-yl)piperazin-1-yl]ethyl}amine;
6-({2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl]ethylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl]ethylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
{2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl]ethyl}-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amine;
6-({2-[4-(6-methoxy-[1,5]naphthyridin-4-yl)-3,6-dihydro-2H-pyridin-1-yl]ethylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;
N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;
N-methyl-N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;
N-methyl-N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

N-(2-{1-[3-chloro-6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl} ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

7-{{(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)oxy}methyl}-2,3-dihydro[1,4]dioxine[2,3-c]pyridine;

N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;

N-methyl-N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;

N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

N-methyl-N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

6-{{(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]hexahydro-1H-1,4-diazepin-1-yl}ethyl)amino}methyl}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;

N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]hexahydro-1H-1,4-diazepin-1-yl}ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

6-{{(2-{1R,4R}-5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2,5-diazabicyclo[2.2.1]hept-2-yl}ethyl)amino}methyl}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;

6-{{(1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl)amino}methyl}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;

6-{{(2-{4-hydroxy-1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)amino}methyl}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;

6-{{(2-{4-hydroxy-1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)amino}methyl}-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one;

N-(2-{4-hydroxy-1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

6-{{(2-{4-[7-fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)amino}methyl}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; or

6-{{(2-{4-[7-fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)amino}methyl}-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; or

a pharmaceutically acceptable salt thereof.

11. (Previously presented): A pharmaceutical composition, comprising a compound or salt according to claim 1 and a pharmaceutically acceptable carrier.

12. (Previously presented): A method of treating bacterial infections in mammals, which comprises administering to a mammal in need thereof an effective amount of a compound or salt according to claim 1.
13. (Previously presented) A method according to claim 12, wherein the mammal is a human.
14. (Previously presented) A compound or salt according to claim 1, wherein R¹² is an aromatic heterocyclic ring (A) having 8-11 ring atoms including 2-4 heteroatoms of which at least one is N or NR¹³, in which preferably Y² contains 2-3 heteroatoms, one of which is S and 1-2 are N, with one N bonded to X³.
15. (Previously presented) A compound or salt according to claim 1, wherein R¹² has a heterocyclic ring (A) having ring (a) aromatic selected from optionally substituted benzo and pyrido and ring (b) non-aromatic and in which Y² has 3-5 atoms including a heteroatom bonded to X⁵ selected from NR¹³, O or S and NHCO bonded via N to X³, or O bonded to X³.
16. (Previously presented) A compound or salt according to claim 1, wherein R¹² is:
3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl,
3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl, or
2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl.
17. (Previously presented) A compound according to claim 1, wherein the compound is:
6-({2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethylamino} methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({2-[1-(3-chloro-6-methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({2-[4-(6-methoxynaphthyridin-4-yl)piperazin-1-yl] ethylamino} methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl]ethylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-[(2-{4-hydroxy-1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)amino]methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; or
6-{[(2-{4-[7-fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}

ethyl)amino]methyl}-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; or
a pharmaceutically acceptable salt thereof.

18. (Currently amended) A compound according to claim 1, wherein the compound is:

6-(*{2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethylamino}* methyl)-4*H*-pyrido[3,2-b][1,4]thiazin-3-one;
6-(*{2-[1-(3-chloro-6-methoxy-[1,5]naphthyridin-4-yl)phenyl]*ethylamino}methyl)-4*H*-pyrido[3,2-b][1,4]thiazin-3-one;
6-(*{2-[4-(6-methoxynaphthyridin-4-yl)piperazin-1-yl]*ethylamino}methyl)-4*H*-pyrido[3,2-b][1,4]thiazin-3-one;
6-(*{2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl]*ethylamino}methyl)-4*H*-pyrido[3,2-b][1,4]thiazin-3-one;
N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-b][1,4]thiazine-6-carboxamide;
N-methyl-N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-b][1,4]thiazine-6-carboxamide;
N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-b][1,4]thiazine-6-carboxamide;
N-methyl-N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-b][1,4]thiazine-6-carboxamide;
6-[(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]hexahydro-1*H*-1,4-diazepin-1-yl}ethyl)amino]methyl)-2*H*-pyrido[3,2-b][1,4]thiazin-3(4*H*)-one;
6-[(2-{(1*R*,4*R*)-5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2,5-diazabicyclo[2.2.1]hept-2-yl}ethyl)amino]methyl)-2*H*-pyrido[3,2-b][1,4]thiazin-3(4*H*)-one;
6-[(1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl)amine]methyl)-2*H*-pyrido[3,2-b][1,4]thiazin-3(4*H*)-one;
6-[(2-{4-hydroxy-1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)amino]methyl)-2*H*-pyrido[3,2-b][1,4]thiazin-3(4*H*)-one; or
6-[(2-{4-[7-fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)amino]methyl)-2*H*-pyrido[3,2-b][1,4]thiazin-3(4*H*)-one; or
a pharmaceutically acceptable salt thereof.

19. (Currently amended) A compound according to claim 1, wherein the compound is:

(2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-{2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethyl}amine;
{2-[1-(3-chloro-6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethyl}-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amine;
(2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-{2-[4-(6-methoxynaphthyridin-4-yl)piperizin-1-yl]ethyl}amine;
{2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl]ethyl}-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amine; or
~~7-[(2-[4-(6-(methyloxy)-1,5-naphthyridin-4-yl)-1-piperazinyl]ethyl)oxy]methyl}-2,3-dihydro[1,4]dioxino[2,3-c]pyridine, or
a pharmaceutically acceptable salt thereof.~~

20. (Previously presented) A pharmaceutical composition, comprising a compound or salt according to claim 10 and a pharmaceutically acceptable carrier.

21. (Previously presented) A method of treating bacterial infections in a human, which comprises administering to a human in need thereof an effective amount of a compound or salt according to claim 10.

22. (New) A compound according to claim 1 wherein R¹⁰ is H.